Real-world use of nirmatrelvir–ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study

BACKGROUND: Nirmatrelvir is a protease inhibitor with in-vitro activity against SARS-CoV-2, and ritonavir-boosted nirmatrelvir can reduce the risk of progression to severe COVID-19 among individuals at high risk infected with delta and early omicron variants. However, less is known about the effecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Aggarwal, Neil R, Molina, Kyle C, Beaty, Laurel E, Bennett, Tellen D, Carlson, Nichole E, Mayer, David A, Peers, Jennifer L, Russell, Seth, Wynia, Matthew K, Ginde, Adit A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014040/
https://www.ncbi.nlm.nih.gov/pubmed/36780912
http://dx.doi.org/10.1016/S1473-3099(23)00011-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014040/
https://www.ncbi.nlm.nih.gov/pubmed/36780912
http://dx.doi.org/10.1016/S1473-3099(23)00011-7

Ejemplares similares